COSCIENS Biopharma Inc
TSX:CSCI
COSCIENS Biopharma Inc
EPS (Diluted)
COSCIENS Biopharma Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
COSCIENS Biopharma Inc
TSX:CSCI
|
EPS (Diluted)
-$5
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-69%
|
CAGR 10-Years
39%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
EPS (Diluted)
CA$0
|
CAGR 3-Years
49%
|
CAGR 5-Years
-130%
|
CAGR 10-Years
N/A
|
|
|
Theratechnologies Inc
TSX:TH
|
EPS (Diluted)
$0
|
CAGR 3-Years
29%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-5%
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
EPS (Diluted)
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
EPS (Diluted)
-$3
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
|
Spectral Medical Inc
TSX:EDT
|
EPS (Diluted)
CA$0
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-7%
|
|
COSCIENS Biopharma Inc
Glance View
COSCIENS Biopharma Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
See Also
What is COSCIENS Biopharma Inc's EPS (Diluted)?
EPS (Diluted)
-5.6
USD
Based on the financial report for Mar 31, 2025, COSCIENS Biopharma Inc's EPS (Diluted) amounts to -5.6 USD.
What is COSCIENS Biopharma Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
39%
Over the last year, the EPS (Diluted) growth was 13%. The average annual EPS (Diluted) growth rates for COSCIENS Biopharma Inc have been -40% over the past three years , -69% over the past five years , and 39% over the past ten years .